ÍøÆØÃÅ

According to ³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Recombinant AAV gene therapy is a key innovation area in cell & gene therapy

Recombinant AAV gene therapy is a technique that uses recombinant adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target tissues. AAVs have gained attention due to their ability to provide long-term expression of therapeutic genes without inducing an immune response. Recombinant AAVs are engineered to carry specific therapeutic genes and are used to treat a range of genetic and acquired diseases.

³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 230+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant AAV gene therapy.

Key players in recombinant AAV gene therapy – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to recombinant AAV gene therapy

(Takeda) is one of the leading patent filers in recombinant AAV gene therapy. Takeda is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of medications. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder. Its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. Encoded Therapeutics and Genethon are some of the other key patent filers in recombinant AAV gene therapy.

In terms of application diversity, F. Hoffmann-La Roche leads the pack, while UniQure and Regeneron Pharmaceuticals stood in the second and third positions, respectively.

By means of geographic reach, held the top position, followed by Genepod Therapeutics and .

To further understand the key themes and technologies disrupting the pharmaceutical industry, access ³Ò±ô´Ç²ú²¹±ô¶Ù²¹³Ù²¹â€™s latest thematic research report on .